The agreement will focus on developing the manufacturing platform for PTH-CBD, that will allow BiologicsMD to conduct Phase I studies. BiologicsMD president Paul Mlakar said Cytovance expertise will
The collaboration will leverage BioInvent’s F.I.R.S.T. technology, a functional approach to therapeutic antibody discovery. The research team will provide the collaboration with biological pathways for the development of
Pierre Fabre, as contract manufacturer, will produce the active ingredient in ANX-188 for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to
Toctino is used to treat adults with severe chronic hand eczema that is refractory to treatment with potent topical corticosteroids. Under the agreement Stiefel will be responsible for
The research collaboration will focus on three neglected tropical diseases (NTDs), leishmaniasis, Chagas disease, and sleeping sickness. Astellas drug discovery research senior vice president Shin-ichi Tsukamoto said the
The clearance allows BacTx test use on leukocyte-reduced whole blood-derived platelet units, a type of platelet preparation which shows bacterial contamination. In the studies reported to the FDA,
Galeterone disrupts androgen receptor (AR) signaling, the key driver of CRPC, through a novel triple mechanism of action. The oral drug selectively inhibits CYP17 lyase to prevent testosterone
The new member of the group will be producing starting materials, intermediates and other fine chemical products for pharma and non-pharma applications in industrial quantities. The new 55,000m2
The company plans to begin a Phase II proof of concept study of AVP-923 during the third calendar quarter of 2012. Avanir Pharmaceuticals R&D senior vice president Joao
The company has also unveiled Openvas Co, a combination preparation for use with a diuretic. Openvas and Openvas Co are the first pharmaceuticals marketed by a Daiichi Sankyo
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.